Vas Narasimhan to lead Sandoz’biosimilars business

Munich, Germany, March 27, 2014 – Sandoz announced today that Vasant (Vas) Narasimhan, MD, MPP, has been appointed Head of Sandoz Biopharmaceuticals & Oncology Injectables effective April 1, 2014. Vas, currently Global Head of Development at Novartis Vaccines, succeeds Ameet Mallik who will take on a new leadership role at Novartis Oncology. Vas will be responsible for biosimilars, oncology injectables, the biotechnology contract manufacturing business, as well as Sandoz’ industry-leading biosimilars pipeline.

“I am deeply grateful for Ameet’s outstanding …

/by

Sandoz receives approval for biosimilar filgrastim in Japan

  • Sandoz Filgrastim approved in all indications as the reference product
  • Sandoz becomes first company to secure approval for two biosimilars in Japan
  • Approval marks continued expansion of Sandoz’ biosimilar business
…
/by

Tuberculosis remains a global health challenge; Sandoz continues commitment to fighting the disease

March 21, 2014 – Despite great progress made in the fight to eradicate Tuberculosis (TB), the disease remains a global killer and disproportionately affects the world’s poor. Sandoz, a leading provider of high-quality, affordable generic medicines, has the opportunity to significantly contribute to the fight against TB.

Tuberculosis (TB) is second only to HIV/AIDS as the greatest killer worldwide due to a single infectious agent, according to the World Health Organization. In 2012, 8.6 million people fell ill with TB and 1.3 million died from TB.

…

/by

Sandoz expands Tuberculosis activities in Africa

March 19, 2014 – The Sandoz Tuberculosis (TB) program is increasing its reach in Africa. Sandoz is expanding its Tuberculosis portfolio as well as its Corporate Responsibility initiatives to support positive health outcomes for more patients and ultimately, contribute towards the eradication of the disease.

Sandoz contributes to fighting Tuberculosis in Egypt

In Egypt, TB constitutes the second most important public health problem, after schistosomiasis. Although Egypt has relatively low levels of TB according to data from the World Health …

/by

Sandoz expands Tuberculosis activities in Africa

March 19, 2014 – The Sandoz Tuberculosis (TB) program is increasing its reach in Africa. Sandoz is expanding its Tuberculosis portfolio as well as its Corporate Responsibility initiatives to support positive health outcomes for more patients and ultimately, contribute towards the eradication of the disease.

Sandoz contributes to fighting Tuberculosis in Egypt

In Egypt, TB constitutes the second most important public health problem, after schistosomiasis. Although Egypt has relatively low levels of TB according to data from the World Health …

/by